Human insulin 30/70 — Competitive Intelligence Brief

Human insulin 30/70 (Human insulin 30/70) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin, biphasic/fixed-ratio combination. Area: Diabetes.

marketed Insulin, biphasic/fixed-ratio combination Insulin receptor Diabetes Small molecule

Target snapshot

Human insulin 30/70 (Human insulin 30/70) — Eli Lilly and Company. Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human insulin 30/70 TARGET	Human insulin 30/70	Eli Lilly and Company	marketed	Insulin, biphasic/fixed-ratio combination	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin, biphasic/fixed-ratio combination class)

1. Eli Lilly and Company · 1 drug in this class